{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T03:08:34Z","timestamp":1787972914802,"version":"build-2784847793"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Comparison of clinical response to methotrexate between anti-SSA antibody-positive and -negative patients with methotrexate-na\u00efve rheumatoid arthritis and investigate the reasons for the differences in the response. For this multicenter retrospective cohort study, a total of 210 consecutive patients with rheumatoid arthritis who newly initiated methotrexate were recruited. The effects of anti-SSA antibody positivity on achieving a low disease activity according to the 28-joint Disease Activity Score based on C-reactive protein after 6 months of methotrexate administration were investigated using a logistic regression analysis. This study involved 32 and 178 anti-SSA antibody-positive and -negative patients, respectively. The rate of achieving low disease activity according to the 28-joint Disease Activity Score based on C-reactive protein at 6 months was significantly lower in the anti-SSA antibody-positive group than in the anti-SSA antibody-negative group (56.2% vs. 75.8%, <jats:italic>P<\/jats:italic> = 0.030). After 6 months, anti-SSA antibody-positive patients had significantly higher scores on the visual analogue scale (median [interquartile range]: 22 [15\u201341] vs. 19 [5\u201330], <jats:italic>P<\/jats:italic> = 0.038) and were frequently prescribed nonsteroidal anti-inflammatory drugs (37.5% vs. 18.0%, <jats:italic>P<\/jats:italic> = 0.018). In conclusion, the presence of anti-SSA antibodies might be a predictive factor for insufficient responses to treat-to-target strategy in rheumatoid arthritis. Residual pain might contribute to the reduced clinical response to methotrexate in anti-SSA antibody-positive patients with rheumatoid arthritis.<\/jats:p>","DOI":"10.1371\/journal.pone.0271921","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T17:33:54Z","timestamp":1658511234000},"page":"e0271921","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effects of anti-SSA antibodies on the response to methotrexate in rheumatoid arthritis: A retrospective multicenter observational study"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1393-2654","authenticated-orcid":true,"given":"Daisuke","family":"Waki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroya","family":"Tamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritsuko","family":"Yokochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Kido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriko","family":"Yagyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Yanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1020-0818","authenticated-orcid":true,"given":"Ken-Ei","family":"Sada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"issue":"4","key":"pone.0271921.ref001","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: Recommendations of an international task force","volume":"69","author":"JS Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"pone.0271921.ref002","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41584-019-0170-5","article-title":"Treat-to-target in rheumatoid arthritis\u2014are we there yet?.","volume":"15","author":"R. van Vollenhoven","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"pone.0271921.ref003","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.semarthrit.2018.06.003","article-title":"Unmet needs in the treatment of rheumatoid arthritis. An observational study and a real-life experience from a single university center","volume":"48","author":"E Kaltsonoudis","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"pone.0271921.ref004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/s10165-012-0702-1","article-title":"Management of rheumatoid arthritis: the 2012 perspective.","volume":"23","author":"H Yamanaka","year":"2013","journal-title":"Mod Rheumatol"},{"issue":"6","key":"pone.0271921.ref005","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"JS Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"pone.0271921.ref006","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/acr.20188","article-title":"Predictors for remission in rheumatoid arthritis patients: A systematic review","volume":"62","author":"W Katchamart","year":"2010","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"6","key":"pone.0271921.ref007","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1136\/ard.2003.010611","article-title":"Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study","volume":"63","author":"L Gossec","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"pone.0271921.ref008","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3899\/jrheum.100514","article-title":"Prognostic factors of radiological damage in rheumatoid arthritis: A 10-year retrospective study","volume":"38","author":"TE Markatseli","year":"2011","journal-title":"J Rheumatol"},{"issue":"3","key":"pone.0271921.ref009","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/rheumatology\/38.3.228","article-title":"Does the age of onset of rheumatoid arthritis influence phenotype?: A prospective study of outcome and prognostic factors.","volume":"38","author":"CT Pease","year":"1999","journal-title":"Rheumatology (Oxford)."},{"issue":"11","key":"pone.0271921.ref010","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.3899\/jrheum.101295","article-title":"Anti-Ro\/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis","volume":"38","author":"R Matsudaira","year":"2011","journal-title":"J Rheumatol"},{"issue":"6","key":"pone.0271921.ref011","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3109\/14397595.2016.1153567","article-title":"Association of anti-Ro\/SSA antibody with response to biologics in patients with rheumatoid arthritis","volume":"26","author":"S Hagiwara","year":"2016","journal-title":"Mod Rheumatol"},{"issue":"4","key":"pone.0271921.ref012","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s10067-007-0812-x","article-title":"Clinical significance of anti-Ro antibodies in rheumatoid arthritis","volume":"27","author":"E Schneeberger","year":"2008","journal-title":"Clin Rheumatol"},{"issue":"3","key":"pone.0271921.ref013","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"FC Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"issue":"9","key":"pone.0271921.ref014","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"D Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"pone.0271921.ref015","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren\u2019s syndrome: A consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"CH Shiboski","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"pone.0271921.ref016","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1136\/annrheumdis-2016-210283","article-title":"Discordance between tender and swollen joint count as well as patient\u2019s and evaluator\u2019s global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study","volume":"76","author":"B Michelsen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"pone.0271921.ref017","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/ard.2007.084459","article-title":"Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate","volume":"68","author":"G Wells","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"pone.0271921.ref018","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/annrheumdis-2012-201491","article-title":"Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index","volume":"71","author":"D Aletaha","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"pone.0271921.ref019","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/ard.2006.054205","article-title":"Comparison of disease activity score (DAS)28-erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values","volume":"66","author":"E Inoue","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"pone.0271921.ref020","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/ard.2011.149765","article-title":"American College of Rheumatology\/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"70","author":"DT Felson","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"pone.0271921.ref021","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1080\/01621459.1986.10478280","article-title":"Multiple imputation for interval estimation from simple random samples with ignorable nonresponse","volume":"81","author":"DB Rubin","year":"1986","journal-title":"J Am Stat Assoc"},{"issue":"14","key":"pone.0271921.ref022","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1002\/sim.7654","article-title":"Bootstrap inference when using multiple imputation.","volume":"37","author":"M Schomaker","year":"2018","journal-title":"Stat Med"},{"issue":"1","key":"pone.0271921.ref023","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13075-020-02189-w","article-title":"Overlapping Sjogren\u2019s syndrome reduces the probability of reaching target in rheumatoid arthritis patients: a propensity score matched real-world cohort from 2009 to 2019","volume":"22","author":"H Zhang","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"pone.0271921.ref024","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/rheumatology\/keu400","article-title":"Clinical characteristics of RA patients with secondary SS and association with joint damage.","volume":"54","author":"LE Brown","year":"2015","journal-title":"Rheumatology (Oxford)."},{"issue":"6","key":"pone.0271921.ref025","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/rheumatology\/kes374","article-title":"Characteristics of Sj\u00f6gren\u2019s syndrome in rheumatoid arthritis","volume":"52","author":"J He","year":"2013","journal-title":"Rheumatology (Oxford)."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0271921","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T17:34:18Z","timestamp":1658511258000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0271921"}},"subtitle":[],"editor":[{"given":"Masataka","family":"Kuwana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":25,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0271921","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,22]]}}}